KHK7580: Phase III started

Kyowa Hakko Kirin began a double-blind, dose-escalation, Japanese Phase III trial to compare oral KHK7580 once daily for 30 weeks vs. oral Regpara cinacalcet in about 600 patients. Kyowa has rights t...